Wide Ranks

KPRX

Kiora Pharmaceuticals, Inc.

3.57

Top Statistics
Market Cap 10 M Forward PE -1.49 Revenue Growth 0.00 %
Current Ratio 19.22 Trailing PE 3.40 Earnings Growth 0.00 %
Profit Margins 19.98 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -2.71 Enterprise / Revenue -1.07 Price To Sales Trailing12 Months 0.6687
Profitability
Profit Margins 19.98 % Operating Margins -12123.26 %
Balance Sheet
Total Cash 27 M Total Cash Per Share 9.37 Total Debt 82323
Total Debt To Equity 0.2490 Current Ratio 19.22 Book Value Per Share 7.14
All Measures
Short Ratio 27.00 % Message Board Id finmb_27817978 Shares Short Prior Month 5243
Return On Equity 0.1369 City Encinitas Uuid 0a06c299-968e-31d2-9678-be3e3334b429
Previous Close 3.46 First Trade Date Epoch Utc 1 B Book Value 7.14
Beta -0.2940 Total Debt 82323 Volume 71009
Price To Book 0.5003 Last Split Date 1 B Fifty Two Week Low 3.00
Total Cash Per Share 9.37 Total Revenue 16 M Shares Short Previous Month Date 1 B
Target Median Price 40.50 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins -12123.26 % Target Mean Price 40.50 Net Income To Common 2 M
Short Percent Of Float 0.0012 Implied Shares Outstanding 3 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 20640 Average Volume10days 20640
Total Cash 27 M Next Fiscal Year End 1 B Revenue Per Share 7.42
Held Percent Insiders 0.0231 Ebitda Margins 39.47 % Trailing PE 3.40
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 3.46
Target Low Price 27.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 3.49
Open 3.70 Free Cashflow 1 M State CA
Dividend Yield 0.00 % Return On Assets 0.1296 Time Zone Short Name EST
Trailing Eps 1.05 Day Low 3.46 Address1 332 Encinitas Boulevard
Shares Outstanding 3 M Price Hint 4 Target High Price 54.00
Website https://www.kiorapharma.com 52 Week Change -0.2328 Average Volume 24809
Forward Eps -2.23 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 1901.70 % Last Split Factor 1:9 Regular Market Day High 3.72
Is_sp_500 False Profit Margins 19.98 % Debt To Equity 0.2490
Fifty Two Week High 8.98 Day High 3.72 Shares Short 3613
Regular Market Open 3.70 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue -1.07 Revenue Growth 0.00 % Shares Percent Shares Out 0.0012
Operating Cashflow 4 M Currency USD Time Zone Full Name America/New_York
Market Cap 10 M Is_nasdaq_100 False Zip 92024
Quote Type EQUITY Industry Biotechnology Long Name Kiora Pharmaceuticals, Inc.
Regular Market Day Low 3.46 Held Percent Institutions 0.4834 Current Price 3.57
Address2 Suite 102 Enterprise To Ebitda -2.71 Financial Currency USD
Current Ratio 19.22 Gross Margins 71.30 % Industry Disp Biotechnology
Number Of Analyst Opinions 2 Country United States Float Shares 1 M
Two Hundred Day Average 4.34 Enterprise Value -17136240 Price To Sales Trailing12 Months 0.6687
Forward PE -1.49 Regular Market Volume 71009 Ebitda 6 M
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States.

Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials indicated for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.

The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, currently under phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; KIO-101, an eye drop for the treatment of ocular presentation of rheumatoid arthritis; and KIO-201, an eye drop for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair.

It has commercialization agreement with 4SC Discovery GmbH, for KIO-101; and collaboration agreement with Théa Open Innovation for the development KIO-301.

The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021.

Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.